SRNE
Sorrento Therapeutics, Inc.
Price Chart
Latest Quote
$0.00
-0.00 (-40.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 501,682 |
Stock Information
| Shares Outstanding | 551.28M |
| Total Debt | $207.60M |
| Cash Equivalents | $80.64M |
| Revenue | $64.27M |
| Net Income | $-548.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $496K |
| EPS (TTM) | $-0.15 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $134.61M |
| Sales | $64.27M |
| Income | $-548.00M |
| Book/sh | $-0.38 |
| Cash/sh | $0.15 |
| Employees | 949 |
Financial Ratios
| Quick Ratio | 0.34 |
| Current Ratio | 0.41 |
Returns & Margins
| ROA | -40.81% |
| Gross Margin | -245.01% |
| Operating Margin | -510.93% |
Ownership
| Institutional Ownership | 0.06% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 0.01 |
| P/B | -0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | 56.25 |
| ATR | 0.0007 |
| Shares Float | 539.11M |
| Short Float | 11.96% |
| Short Ratio | 4.96 |
| Volatility | 0.15 |
| Rel Volume | 0.68 |
Performance History
| Week | +80.00% |
| Month | +80.00% |
| Quarter | -76.32% |
| 6 Months | -76.92% |
| YTD | -71.43% |
| Year | -57.14% |
| 3 Years | -99.74% |
| 5 Years | -99.99% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.00 | 230,212 |
| 2026-06-11 | $0.00 | 742,627 |
| 2026-06-10 | $0.00 | 449,367 |
| 2026-06-09 | $0.00 | 720,225 |
| 2026-06-08 | $0.00 | 39,625 |
| 2026-06-05 | $0.00 | 2,486,100 |
| 2026-06-04 | $0.00 | 35,334 |
| 2026-06-03 | $0.00 | 23,504 |
| 2026-06-02 | $0.00 | 668,075 |
| 2026-06-01 | $0.00 | 263,806 |
| 2026-05-29 | $0.00 | 74,974 |
| 2026-05-28 | $0.00 | 97,646 |
| 2026-05-27 | $0.00 | 128,697 |
| 2026-05-26 | $0.00 | 35,375 |
| 2026-05-22 | $0.00 | 41,481 |
| 2026-05-21 | $0.00 | 25,504 |
| 2026-05-20 | $0.00 | 277,959 |
| 2026-05-19 | $0.00 | 144,469 |
| 2026-05-18 | $0.00 | 233,078 |
| 2026-05-15 | $0.00 | 17,832 |
| 2026-05-14 | $0.00 | 580,170 |
| 2026-05-13 | $0.00 | 128,655 |
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
đ° Latest News
No news articles available at the moment. Check back later for updates on SRNE.
Period:
Loading...
Income Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Revenue | ||
| Reconciled Cost Of Revenue | $24,532,000 | $4,709,000 |
| Cost Of Revenue | $33,452,000 | $13,031,000 |
| Total Revenue | $62,839,000 | $52,904,000 |
| Operating Revenue | $62,839,000 | $52,904,000 |
| Expenses | ||
| Interest Expense | $8,574,000 | $10,224,000 |
| Total Expenses | $441,340,000 | $420,949,000 |
| Other Income Expense | $-174,672,000 | $-84,259,000 |
| Other Non Operating Income Expenses | $736,000 | $-28,845,000 |
| Net Non Operating Interest Income Expense | $-8,574,000 | $-10,224,000 |
| Interest Expense Non Operating | $8,574,000 | $10,224,000 |
| Operating Expense | $407,888,000 | $407,918,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-572,843,000 | $-428,325,000 |
| Net Interest Income | $-8,574,000 | $-10,224,000 |
| Normalized Income | $-398,189,407 | $-376,926,445 |
| Net Income From Continuing And Discontinued Operation | $-572,843,000 | $-428,325,000 |
| Total Operating Income As Reported | $-504,315,000 | $-401,451,000 |
| Average Dilution Earnings | $0 | $0 |
| Net Income Common Stockholders | $-572,843,000 | $-428,325,000 |
| Net Income | $-572,843,000 | $-428,325,000 |
| Net Income Including Noncontrolling Interests | $-577,757,000 | $-429,138,000 |
| Net Income Continuous Operations | $-577,757,000 | $-429,138,000 |
| Earnings From Equity Interest Net Of Tax | $-18,426,000 | $-126,000 |
| Pretax Income | $-561,747,000 | $-462,528,000 |
| Special Income Charges | $-98,805,000 | $-40,101,000 |
| Operating Income | $-378,501,000 | $-368,045,000 |
| Depreciation Amortization Depletion Income Statement | $4,325,000 | $4,140,000 |
| Depreciation And Amortization In Income Statement | $4,325,000 | $4,140,000 |
| Amortization Of Intangibles Income Statement | $4,325,000 | $4,140,000 |
| Gross Profit | $29,387,000 | $39,873,000 |
| Per Share | ||
| Diluted EPS | $-1.37 | $-1.45 |
| Basic EPS | $-1.37 | $-1.45 |
| Other | ||
| Tax Effect Of Unusual Items | $-754,407 | $-4,015,445 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-364,520,000 | $-384,428,000 |
| Total Unusual Items | $-175,408,000 | $-55,414,000 |
| Total Unusual Items Excluding Goodwill | $-175,408,000 | $-55,414,000 |
| Reconciled Depreciation | $13,245,000 | $12,462,000 |
| EBITDA (Bullshit earnings) | $-539,928,000 | $-439,842,000 |
| EBIT | $-553,173,000 | $-452,304,000 |
| Diluted Average Shares | $419,315,000 | $294,774,000 |
| Basic Average Shares | $419,315,000 | $294,774,000 |
| Diluted NI Availto Com Stockholders | $-572,843,000 | $-428,325,000 |
| Minority Interests | $4,914,000 | $813,000 |
| Tax Provision | $-2,416,000 | $-33,516,000 |
| Other Special Charges | $50,015,000 | $30,903,000 |
| Impairment Of Capital Assets | $124,190,000 | $0 |
| Restructuring And Mergern Acquisition | $-75,400,000 | $9,198,000 |
| Gain On Sale Of Security | $-76,603,000 | $-15,313,000 |
| Amortization | $4,325,000 | $4,140,000 |
| Research And Development | $221,226,000 | $206,922,000 |
| Selling General And Administration | $182,337,000 | $196,856,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-235,776,000 | $-260,482,000 |
| Total Assets | $472,840,000 | $694,818,000 |
| Total Non Current Assets | $376,467,000 | $521,829,000 |
| Other Non Current Assets | $3,685,000 | $4,830,000 |
| Goodwill And Other Intangible Assets | $217,171,000 | $339,230,000 |
| Other Intangible Assets | $136,902,000 | $259,705,000 |
| Current Assets | $96,373,000 | $172,989,000 |
| Other Current Assets | $3,143,000 | $7,482,000 |
| Prepaid Assets | $8,807,000 | $11,804,000 |
| Inventory | $9,976,000 | $8,106,000 |
| Receivables | $24,469,000 | $18,715,000 |
| Accounts Receivable | $24,469,000 | $18,715,000 |
| Cash Cash Equivalents And Short Term Investments | $49,978,000 | $126,882,000 |
| Cash And Cash Equivalents | $23,634,000 | $36,665,000 |
| Debt | ||
| Net Debt | $11,782,000 | $105,942,000 |
| Total Debt | $134,504,000 | $237,577,000 |
| Long Term Debt And Capital Lease Obligation | $104,338,000 | $194,058,000 |
| Long Term Debt | $19,130,000 | $110,627,000 |
| Current Debt And Capital Lease Obligation | $30,166,000 | $43,519,000 |
| Current Debt | $16,286,000 | $31,980,000 |
| Other Current Borrowings | $16,286,000 | $31,980,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $494,509,000 | $616,689,000 |
| Total Non Current Liabilities Net Minority Interest | $166,587,000 | $477,236,000 |
| Other Non Current Liabilities | $54,260,000 | $126,110,000 |
| Derivative Product Liabilities | $300,000 | $35,700,000 |
| Non Current Deferred Liabilities | $7,689,000 | $121,368,000 |
| Non Current Deferred Taxes Liabilities | $591,000 | $2,426,000 |
| Current Liabilities | $327,922,000 | $139,453,000 |
| Other Current Liabilities | $8,197,000 | $7,934,000 |
| Current Deferred Liabilities | $652,000 | $1,108,000 |
| Payables And Accrued Expenses | $288,907,000 | $86,892,000 |
| Payables | $47,515,000 | $27,414,000 |
| Accounts Payable | $47,515,000 | $27,414,000 |
| Equity | ||
| Common Stock Equity | $-18,605,000 | $78,748,000 |
| Total Equity Gross Minority Interest | $-21,669,000 | $78,129,000 |
| Stockholders Equity | $-18,605,000 | $78,748,000 |
| Gains Losses Not Affecting Retained Earnings | $1,501,000 | $1,026,000 |
| Retained Earnings | $-1,959,447,000 | $-1,386,604,000 |
| Long Term Equity Investment | $17,176,000 | $51,271,000 |
| Other | ||
| Treasury Shares Number | $7,568,182 | $7,568,182 |
| Ordinary Shares Number | $515,248,955 | $314,573,225 |
| Share Issued | $522,817,137 | $322,141,407 |
| Tangible Book Value | $-235,776,000 | $-260,482,000 |
| Invested Capital | $16,811,000 | $221,355,000 |
| Working Capital | $-231,549,000 | $33,536,000 |
| Capital Lease Obligations | $99,088,000 | $94,970,000 |
| Total Capitalization | $525,000 | $189,375,000 |
| Minority Interest | $-3,064,000 | $-619,000 |
| Treasury Stock | $49,464,000 | $49,464,000 |
| Additional Paid In Capital | $1,988,753,000 | $1,513,758,000 |
| Capital Stock | $52,000 | $32,000 |
| Common Stock | $52,000 | $32,000 |
| Non Current Deferred Revenue | $7,098,000 | $118,942,000 |
| Long Term Capital Lease Obligation | $85,208,000 | $83,431,000 |
| Current Deferred Revenue | $652,000 | $1,108,000 |
| Current Capital Lease Obligation | $13,880,000 | $11,539,000 |
| Current Accrued Expenses | $241,392,000 | $59,478,000 |
| Investments And Advances | $17,176,000 | $51,271,000 |
| Goodwill | $80,269,000 | $79,525,000 |
| Net PPE | $138,435,000 | $126,498,000 |
| Accumulated Depreciation | $-51,420,000 | $-43,490,000 |
| Gross PPE | $189,855,000 | $169,988,000 |
| Leases | $16,158,000 | $15,529,000 |
| Construction In Progress | $18,230,000 | $7,878,000 |
| Other Properties | $86,464,000 | $85,173,000 |
| Machinery Furniture Equipment | $69,003,000 | $61,408,000 |
| Properties | $0 | $0 |
| Other Inventories | $-24,000 | $106,000 |
| Finished Goods | $3,400,000 | $4,700,000 |
| Raw Materials | $6,600,000 | $3,300,000 |
| Other Short Term Investments | $26,344,000 | $90,217,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-307,514,000 | $-290,692,000 |
| Operating Activities | ||
| Operating Cash Flow | $-293,857,000 | $-281,821,000 |
| Cash Flow From Continuing Operating Activities | $-293,857,000 | $-281,821,000 |
| Operating Gains Losses | $68,020,000 | $22,134,000 |
| Investing Activities | ||
| Capital Expenditure | $-13,657,000 | $-8,871,000 |
| Investing Cash Flow | $-28,518,000 | $79,847,000 |
| Cash Flow From Continuing Investing Activities | $-28,518,000 | $79,847,000 |
| Financing Activities | ||
| Repurchase Of Capital Stock | $0 | $0 |
| Issuance Of Capital Stock | $402,334,000 | $201,825,000 |
| Financing Cash Flow | $311,718,000 | $181,332,000 |
| Cash Flow From Continuing Financing Activities | $311,718,000 | $181,332,000 |
| Net Other Financing Charges | $426,000 | - |
| Net Common Stock Issuance | $402,334,000 | $201,825,000 |
| Common Stock Issuance | $402,334,000 | $201,825,000 |
| Other | ||
| Repayment Of Debt | $-188,311,000 | $-85,656,000 |
| Issuance Of Debt | $96,071,000 | $49,743,000 |
| Interest Paid Supplemental Data | $1,173,000 | $1,060,000 |
| Income Tax Paid Supplemental Data | $29,000 | $1,200,000 |
| End Cash Position | $23,634,000 | $36,665,000 |
| Beginning Cash Position | $36,665,000 | $56,464,000 |
| Effect Of Exchange Rate Changes | $-2,374,000 | $843,000 |
| Changes In Cash | $-10,657,000 | $-20,642,000 |
| Proceeds From Stock Option Exercised | $1,198,000 | $15,420,000 |
| Common Stock Payments | $0 | $0 |
| Net Issuance Payments Of Debt | $-92,240,000 | $-35,913,000 |
| Net Short Term Debt Issuance | $96,071,000 | $49,743,000 |
| Short Term Debt Issuance | $96,071,000 | $49,743,000 |
| Net Long Term Debt Issuance | $-188,311,000 | $-85,656,000 |
| Long Term Debt Payments | $-188,311,000 | $-85,656,000 |
| Net Investment Purchase And Sale | $0 | $124,767,000 |
| Sale Of Investment | $0 | $124,767,000 |
| Net Business Purchase And Sale | $-14,861,000 | $-36,049,000 |
| Purchase Of Business | $-14,861,000 | $-36,049,000 |
| Net PPE Purchase And Sale | $-13,657,000 | $-8,871,000 |
| Purchase Of PPE | $-13,657,000 | $-8,871,000 |
| Change In Working Capital | $69,551,000 | $-2,791,000 |
| Change In Other Working Capital | $-113,222,000 | $-4,573,000 |
| Change In Payables And Accrued Expense | $191,160,000 | $16,758,000 |
| Change In Accrued Expense | $181,290,000 | $20,636,000 |
| Change In Payable | $9,870,000 | $-3,878,000 |
| Change In Account Payable | $9,870,000 | $-3,878,000 |
| Change In Prepaid Assets | $6,803,000 | $-5,743,000 |
| Change In Inventory | $-9,510,000 | $-6,276,000 |
| Change In Receivables | $-5,680,000 | $-2,957,000 |
| Changes In Account Receivables | $-5,680,000 | $-2,957,000 |
| Other Non Cash Items | $-64,117,000 | $61,251,000 |
| Stock Based Compensation | $74,847,000 | $90,188,000 |
| Asset Impairment Charge | $124,190,000 | $0 |
| Deferred Tax | $-1,836,000 | $-35,927,000 |
| Deferred Income Tax | $-1,836,000 | $-35,927,000 |
| Depreciation Amortization Depletion | $13,245,000 | $12,462,000 |
| Depreciation And Amortization | $13,245,000 | $12,462,000 |
| Earnings Losses From Equity Investments | $18,426,000 | $126,000 |
| Gain Loss On Investment Securities | $76,603,000 | $15,313,000 |
| Net Income From Continuing Operations | $-577,757,000 | $-429,138,000 |
| Long Term Debt Issuance | - | $0 |
| Depreciation | - | $12,462,000 |
Fetched: 2026-02-02